Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 22,258 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Labor Pain
Interventions: Intracutaneous injections; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Health Care Quality, Access, and Evaluation, Delivery of Health Care, Immune System Diseases, HIV Infections
Interventions: Rates of HIV testing and receipt of results, Sexual risk reduction; HIV knowledge improvement; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Healthy Volunteers
Interventions: E2006 2.5 mg, E2006 10 mg, E2006 25 mg, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions: Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Low-back Pain, Chronic Pain
Interventions: Open-label Placebo, Standard Rationale, Mindfulness, Control Rationale; Drug · Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 89 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Appendicitis, Children
Interventions: Patient Activation Tool; Other
Lead sponsor: Peter Minneci; Other
Eligibility: 7 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Blood Loss, Surgical, Blood Loss Anemia
Interventions: Tranexamic Acid; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cognitive Impairment, Disability Physical, Surgery
Interventions: Comprehensive training program, Active control; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections
Interventions: Family-Based Risk Reduction Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Diabetes Mellitus, Type 2, Cancer
Interventions: Nurse-led diabetes care; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Electrical Alternation of Heart, Blood Pressure
Interventions: Energy Drink Brand 1, Energy Drink Brand 2, Placebo; Dietary Supplement · Other
Lead sponsor: University of the Pacific; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Stockton, California

Conditions: Carpal Tunnel Syndrome
Interventions: Group One, Control Group Two; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Non-infectious Uveitis
Interventions: Basiliximab, Placebo; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more

Conditions: Health Adult Subjects
Interventions: Omaveloxolone, Moxifloxacin; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity
Interventions: Hybrid Argon Plasma Coagulation, Endoscopic Sleeve Gastroplasty; Procedure
Lead sponsor: True You Weight Loss; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Smoking Cessation
Interventions: Smiling instead of Smoking, QuitGuide; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative, Morbid Obesity
Interventions: Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision; Drug
Lead sponsor: Pinnacle Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Bronchopulmonary Dysplasia, Apnea of Prematurity
Interventions: Caffeine, Placebo (dextrose); Drug
Lead sponsor: Wayne State University; Other
Eligibility: Up to 4 Weeks
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: Ultrasound Vagus Nerve Stimulation (DECIMA); Device
Lead sponsor: Aucta Technologies, Inc.; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diabetes Complications, Diabetic Neuropathies
Interventions: Muscle power, balance perturbation, aerobic exercise; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 55 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
Interventions: Urinalysis; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Intracutaneous Sterile Water Injections

Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

HOnest Placebos With Explanations: Evaluating Open-Label Placebos for Chronic Pain

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

COgnitive and Physical Exercise to Improve Outcomes After Surgery (COPE-iOS) Study

Family-based HIV Prevention for Adolescent Girls

Pilot RCT Feasibility Study: Cancer and T2D

Impact of Energy Drink Brands on Heart Rhythm

Early Motion Following Carpal Tunnel Release

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

A TQTc Study for Omaveloxolone

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Validation Study

Testing the mHealth App Intervention for Nondaily Smokers "SiS4"

Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic

Early Versus Late Caffeine for ELBW Newborns

Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Bladder Cancer Screening Trial